Novel therapeutic strategies in myelodysplastic syndromes: do molecular genetics help?

Current Opinion in Hematology
Stephen S Chung

Abstract

Many studies over the past decade have together identified genes that are recurrently mutated in the myelodysplastic syndromes (MDS). We will summarize how this information has informed our understanding of disease pathogenesis and behavior, with an emphasis on how this information may inform therapeutic strategies. Genomic sequencing techniques have allowed for the identification of many recurrently mutated genes in MDS, with the most common mutations being found in epigenetic modifiers and components of the splicing machinery. Although many mutations are associated with clinical outcomes and disease phenotypes, at the current time they add relatively little to already robust clinical prognostic algorithms. However, as molecular genetic data are accumulated in larger numbers of patients, it is likely that the clinical significance of co-occurring mutations and less common mutations will come to light. Finally, mutated genes may identify biologically distinct subgroups of MDS that may benefit from novel therapies, and a subset of these genes may themselves serve as therapeutic targets. Advances in our knowledge of the molecular genetics of MDS have significantly improved our understanding of disease biology and promise to impro...Continue Reading

References

May 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lewis R SilvermanJames F Holland
Jul 12, 2003·Leukemia & Lymphoma·Shigeo HoriikeMasafumi Taniwaki
Jul 21, 2005·British Journal of Haematology·Kai BrakensiekUlrich Lehmann
Oct 6, 2006·The New England Journal of Medicine·Alan ListUNKNOWN Myelodysplastic Syndrome-003 Study Investigators
May 3, 2008·The New England Journal of Medicine·Richard F SchlenkUNKNOWN German-Austrian Acute Myeloid Leukemia Study Group
Oct 4, 2008·Blood·Ying JiangJaroslaw P Maciejewski
Apr 25, 2009·British Journal of Haematology·Véronique Gelsi-BoyerDaniel Birnbaum
May 29, 2009·The New England Journal of Medicine·François DelhommeauOlivier A Bernard
Jun 2, 2009·Nature Genetics·Saskia M C LangemeijerJoop H Jansen
Jun 17, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David P SteensmaHagop Kantarjian
Aug 7, 2009·The New England Journal of Medicine·Elaine R MardisTimothy J Ley
Nov 26, 2009·Nature·Lenny DangShinsan M Su
Dec 30, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lanlan ShenJean-Pierre J Issa
Jul 6, 2010·Nature Genetics·Thomas ErnstNicholas C P Cross
Sep 10, 2010·The New England Journal of Medicine·Ramin TehranchiSten Eirik W Jacobsen
Nov 12, 2010·The New England Journal of Medicine·Timothy J LeyRichard K Wilson
Mar 19, 2011·Leukemia·M J WalterT A Graubert
Apr 5, 2011·EMBO Reports·Rasheduzzaman ChowdhuryAkane Kawamura
Apr 27, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin JäderstenGhulam J Mufti
May 18, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Felicitas TholArnold Ganser
Jul 1, 2011·The New England Journal of Medicine·Rafael BejarBenjamin L Ebert
Aug 11, 2011·Blood·Thorsten BraunUNKNOWN Groupe Francophone des Myélodysplasies
Sep 2, 2011·Haematologica·Felicitas TholArnold Ganser
Sep 13, 2011·Nature·Kenichi YoshidaSeishi Ogawa
Oct 15, 2011·The New England Journal of Medicine·E PapaemmanuilUNKNOWN Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium
Dec 14, 2011·The New England Journal of Medicine·Lili WangCatherine J Wu
Dec 14, 2011·Nature Genetics·Timothy A GraubertMatthew J Walter

❮ Previous
Next ❯

Methods Mentioned

BETA
MDS
exome sequencing
transgenic

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Alternative splicing

Alternative splicing a regulated gene expression process that allows a single genetic sequence to code for multiple proteins. Here is that latest research.

Cardiovascular Disease & TET2

Cardiovascular diseases are the number one cause of deaths globally. Tet methylcytosine dioxygenase 2 (TET2)-mediated hematopoiesis has been implicated in accelerating heart failure. Here is the latest research on cardiovascular diseases and TET2.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Zuzana TothovaBenjamin L Ebert
Hematology
Timothy A Graubert, Matthew J Walter
© 2021 Meta ULC. All rights reserved